AI Reads Scans to Predict Hidden Spread in Colorectal Cancer Before Surgery

One of the most consequential questions in colorectal cancer care is also one of the hardest to answer before a scalpel touches the patient: has the tumor already sent cells creeping into the lymphatic or blood vessels that thread through the bowel wall? This phenomenon, known as lymphovascular invasion, or LVI, is invisible to the naked eye during surgery and has traditionally been confirmed only after the resected tissue is sliced, stained, and examined under a microscope by a pathologist. Yet LVI matters enormously. Its presence is strongly associated with poorer survival, higher rates of distant metastasis, and decisions about whether patients need chemotherapy after their operation. A new systematic review and meta-analysis published in BMC Medical Imaging suggests that artificial intelligence, applied to routine preoperative scans, may soon give surgical teams a non-invasive head start on that answer.

The review, led by Yassin Rahnama and colleagues at Tehran University of Medical Sciences, set out to quantify just how well AI models—spanning both handcrafted radiomics and end-to-end deep learning—can predict LVI from preoperative medical imaging such as magnetic resonance imaging, computed tomography, and positron emission tomography. The team searched four major biomedical databases, PubMed, Embase, Scopus, and Web of Science, with coverage extending to October 3, 2025. To be included, studies had to involve patients with histopathologically confirmed colorectal cancer who underwent preoperative imaging that was subsequently analyzed by AI algorithms, with the final diagnosis of LVI established by postoperative pathology serving as the reference standard.

After screening, the researchers assembled 18 retrospective studies encompassing a combined 5,524 patients. Seventeen of those studies reported enough data to be folded into a quantitative meta-analysis. The pooled results were encouraging: sensitivity came in at 0.77, with a 95 percent confidence interval of 0.70 to 0.82, meaning the models correctly flagged roughly three out of four tumors that truly harbored LVI. Specificity was slightly higher at 0.81, with a confidence interval of 0.77 to 0.85, indicating that the algorithms also did a credible job of ruling out invasion when it was absent. The summary receiver operating characteristic curve, a standard way of visualizing diagnostic performance across studies, yielded an area under the curve of 0.84, with a partial AUC of 0.74—a figure the authors characterize as robust for a diagnostic task of this difficulty.

Those headline numbers become more tangible when translated into clinical terms. At a pre-test probability of 38 percent, a plausible prevalence of LVI in a typical colorectal cancer population, the pooled estimates correspond to a positive predictive value of 72 percent and a negative predictive value of 85 percent. In practical terms, a positive AI prediction would meaningfully raise suspicion that a tumor has invaded lymphatic or vascular channels, while a negative prediction would be reassuring in the large majority of cases. That kind of preoperative risk stratification could influence surgical planning, the extent of lymph node dissection, and the timing of conversations about adjuvant therapy—all before the patient is ever anesthetized.

The technical machinery behind these predictions is worth unpacking. Radiomics approaches convert medical images into hundreds or thousands of quantitative features describing tumor shape, texture, intensity, and heterogeneity, which are then fed into machine learning classifiers such as support vector machines or random forests. Deep learning approaches, by contrast, use convolutional neural networks that learn discriminative patterns directly from the pixel data, often capturing subtle image signatures that escape both human perception and manually engineered features. The fact that both families of algorithms converge on similar pooled accuracy suggests that the imaging phenotype of LVI—presumably reflecting tumor biology such as desmoplastic reaction, peritumoral fat infiltration, and altered vascular patterns—carries genuine, extractable signal.

Quality assessment, however, tempers the enthusiasm. The authors applied the QUADAS-2 tool, the standard framework for evaluating bias and applicability in diagnostic accuracy studies, alongside the Radiomics Quality Score 2.0, or RQS 2.0, which grades how rigorously radiomics research is conducted. The mean RQS 2.0 score across the included studies was just 24.7 out of a possible 100 percent scale—equivalent to 44 percent—highlighting substantial methodological shortcomings in the existing literature. Common weaknesses in this field include small single-center cohorts, retrospective designs vulnerable to selection bias, inconsistent image acquisition protocols, and limited reporting of model validation. These deficiencies mean the impressive pooled statistics should be read as a proof of concept rather than a guarantee of real-world performance.

Geography presents another significant caveat. Every one of the 18 included studies was retrospective, and all were conducted in China. That homogeneity raises genuine questions about generalizability. Imaging protocols, scanner vendors, patient demographics, tumor biology, and even the prevalence of LVI itself can differ across populations and healthcare systems, and an algorithm trained on one distribution of data may degrade when deployed in another. The authors are explicit that prospective, multicenter validation in geographically and ethnically diverse populations, together with standardized imaging protocols, is required before broader clinical implementation can be considered. Without such validation, the pooled estimates remain a portrait of what is achievable under research conditions, not what patients should expect at their local hospital.

Even so, the clinical logic of the endeavor is compelling. Current practice leaves surgeons operating on colorectal cancer essentially blind to LVI status, relying on intraoperative judgment and postoperative pathology to guide treatment intensity. A validated AI tool that reads routine MRI or CT scans—imaging most patients already receive during staging—could slot into existing workflows without additional radiation, cost, or invasive procedures. It could help identify patients who might benefit from more extensive lymphadenectomy, flag candidates for neoadjuvant therapy, or enrich clinical trials by preselecting patients at higher risk of occult spread. The negative predictive value of 85 percent, in particular, hints at a role in reassuring both clinicians and patients when the algorithm finds no evidence of vascular invasion.

The study also fits into a broader movement in oncology imaging, where machine learning is being trained to predict molecular and histological features—microsatellite instability, tumor-infiltrating lymphocytes, genetic mutations—directly from radiographic appearances, a paradigm sometimes called radiogenomics. LVI prediction is a natural extension of that agenda because it targets a well-validated prognostic marker with a clear pathological definition and direct treatment implications. The convergence of computer vision, growing archives of digitized pathology-confirmed scans, and standardized reporting frameworks like QUADAS-2 and RQS 2.0 is steadily raising the bar for what counts as credible evidence in this space.

The path from meta-analysis to clinic remains long, but the trajectory is clear. The Tehran-led team, whose work was conducted under PRISMA reporting guidelines and published open access, has provided the most comprehensive quantitative synthesis to date of AI-driven LVI prediction in colorectal cancer imaging. Their verdict is measured: pooled sensitivity of 0.77, specificity of 0.81, and an AUC of 0.84 constitute promising diagnostic accuracy that may serve as a complementary tool for preoperative risk stratification. What happens next depends on whether the field can graduate from retrospective, single-country studies to the kind of prospective, externally validated, protocol-standardized trials that turn clever algorithms into trusted clinical instruments. For the thousands of patients diagnosed with colorectal cancer each year, the prospect of knowing, before surgery, whether their tumor has already begun its silent march through the vasculature is a prize well worth the rigorous validation still to come.

Subject of Research: Artificial intelligence for preoperative prediction of lymphovascular invasion in colorectal cancer imaging

Article Title: Artificial intelligence in predicting lymphovascular invasion in colorectal cancer imaging: a systematic review and meta-analysis

Article References: Rahnama, Y., Ahmadi-Tafti, S. M., Yousefi-Koma, H., Pirahesh, K., Torkaman, N., BaradaranRad, A., Keshvari, A., Salahshour, F., Sedaghat, M., & Delazar, S. (2026). Artificial intelligence in predicting lymphovascular invasion in colorectal cancer imaging: a systematic review and meta-analysis. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02858-3

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02858-3

Keywords: colorectal cancer, lymphovascular invasion, artificial intelligence, radiomics, deep learning, meta-analysis, medical imaging, MRI, diagnostic accuracy, risk stratification, predictive markers, BMC Medical Imaging